Parkinson’s vs. Multiple Sclerosis: How They’re Different
Parkinson’s disease and multiple sclerosis are neurodegenerative diseases that affect your brain and spinal cord. Multiple sclerosis occurs when…
Gene Therapy Studies Underway in Parkinson Disease
June 15, 2021 – by Victoria Johnson Bayer provided an update on their phase 1 and 1b studies of dopaminergic…
Stuart Schlossman
World Brain Day: Hot Topics in Parkinson Disease
This year, the World Federation of Neurology partnered with the International Parkinson and Movement Disorder Society to spotlight advancements in…
Stuart Schlossman
Beyond Motor Symptom Wearing-off in Parkinson’s Disease – What Are We Missing?
Authors: Olivier Rascol , Hubert Fernandez , Per Odin , Joaquim J Ferreira European Neurological Review. 2020;15(Suppl. 1):2–7 Abstract In the treatment of Parkinson’s disease (PD), wearing-off refers…
Stuart Schlossman
APDA – PARKINSON’S AND COVID-19 Q&A
Video produced by and shared with kind authorisation of the American Parkinson’s Disease Association (APDA). This is a video recording…
Stuart Schlossman
New CDC Registry to Monitor MS and Parkinson’s Prevalence and Disease Trends
The National Neurological Conditions Surveillance System creates a mechanism for tracking neurological disorders and identifying environmental triggers. By Brian P.…
Stuart Schlossman
Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder) for Parkinson’s
12/21/2018 First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa Expected…
Stuart Schlossman
